[AFFIN] QoQ TTM Result on 31-Dec-2021 [#4]

Stock
[AFFIN] AFFIN BANK BERHAD
Announcement Date
28-Feb-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
31-Dec-2021 [#4]
Profit Trend
QoQ- 69.58%
YoY- 128.78%
Quarter Report
Latest QR
Upcoming QR
AFFIN's Result
AFFIN's Financial Summary
View:
Show?
TTM Result
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Revenue 3,302,732 2,232,635 2,232,343 2,241,156 2,289,819 2,431,526 2,365,582 24.89%
PBT 1,559,684 830,124 795,852 703,854 492,512 401,023 320,583 186.84%
Tax -150,363 -154,588 -144,557 -123,531 -124,612 -118,461 -95,232 35.55%
NP 1,409,321 675,536 651,295 580,323 367,900 282,562 225,351 239.06%
-
NP to SH 1,368,806 629,643 600,683 526,934 310,723 226,239 175,690 292.51%
-
Tax Rate 9.64% 18.62% 18.16% 17.55% 25.30% 29.54% 29.71% -
Total Cost 1,893,411 1,557,099 1,581,048 1,660,833 1,921,919 2,148,964 2,140,231 -7.83%
-
Net Worth 10,651,747 10,089,296 10,004,334 9,837,087 9,479,468 9,376,478 9,255,069 9.81%
Dividend
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Div 263,870 263,870 263,870 263,870 70,532 70,532 70,532 140.79%
Div Payout % 19.28% 41.91% 43.93% 50.08% 22.70% 31.18% 40.15% -
Equity
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Net Worth 10,651,747 10,089,296 10,004,334 9,837,087 9,479,468 9,376,478 9,255,069 9.81%
NOSH 2,212,329 2,124,062 2,124,062 2,124,062 2,124,062 2,124,062 2,079,791 4.20%
Ratio Analysis
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
NP Margin 42.67% 30.26% 29.18% 25.89% 16.07% 11.62% 9.53% -
ROE 12.85% 6.24% 6.00% 5.36% 3.28% 2.41% 1.90% -
Per Share
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
RPS 153.48 105.11 105.10 106.17 108.70 115.92 113.74 22.08%
EPS 63.61 29.64 28.28 24.96 14.75 10.79 8.45 283.62%
DPS 12.50 12.50 12.50 12.50 3.35 3.36 3.39 138.48%
NAPS 4.95 4.75 4.71 4.66 4.50 4.47 4.45 7.34%
Adjusted Per Share Value based on latest NOSH - 2,124,062
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
RPS 137.48 92.94 92.93 93.29 95.32 101.22 98.47 24.89%
EPS 56.98 26.21 25.00 21.93 12.93 9.42 7.31 292.63%
DPS 10.98 10.98 10.98 10.98 2.94 2.94 2.94 140.52%
NAPS 4.4341 4.1999 4.1646 4.0949 3.9461 3.9032 3.8527 9.81%
Price Multiplier on Financial Quarter End Date
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Date 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 -
Price 1.99 1.88 2.00 1.73 1.69 1.75 1.73 -
P/RPS 1.30 1.79 1.90 1.63 1.55 1.51 1.52 -9.88%
P/EPS 3.13 6.34 7.07 6.93 11.46 16.23 20.48 -71.38%
EY 31.96 15.77 14.14 14.43 8.73 6.16 4.88 249.64%
DY 6.28 6.65 6.25 7.23 1.98 1.92 1.96 117.18%
P/NAPS 0.40 0.40 0.42 0.37 0.38 0.39 0.39 1.70%
Price Multiplier on Announcement Date
30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 CAGR
Date 25/11/22 24/08/22 27/05/22 28/02/22 19/11/21 26/08/21 25/05/21 -
Price 2.43 2.10 2.18 1.77 1.68 1.74 1.70 -
P/RPS 1.58 2.00 2.07 1.67 1.55 1.50 1.49 3.98%
P/EPS 3.82 7.08 7.71 7.09 11.39 16.13 20.12 -66.93%
EY 26.18 14.12 12.97 14.10 8.78 6.20 4.97 202.43%
DY 5.14 5.95 5.73 7.06 1.99 1.93 1.99 88.14%
P/NAPS 0.49 0.44 0.46 0.38 0.37 0.39 0.38 18.45%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment